                         SEQUENCE LISTING

<110>  SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
       PELLECCHIA, Maurizio
 
<120>  TARGETED DELIVERY OF CHEMOTHERAPEUTIC AGENTS

<130>  BURN1450-1WO

<140>  PCT/US2010/028017
<141>  2010-03-19

<150>  US 61/162,176
<151>  2009-03-20

<160>  9     

<170>  PatentIn version 3.5

<210>  1
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct

<400>  1

Tyr Ser Ala Tyr Pro Asp Ser Val Pro Met Met Ser 
1               5                   10          


<210>  2
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MOD_RES
<222>  (10)..(11)
<223>  Nle

<400>  2

Tyr Ser Ala Tyr Pro Asp Ser Val Pro Xaa Xaa Ser 
1               5                   10          


<210>  3
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is optionally Y, S, T, C, N or Q

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is optionally Y, S, T, C, N or Q

<400>  3

Xaa Ser Ala Xaa Pro Asp Ser Val Pro Met Met Ser 
1               5                   10          


<210>  4
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa optionally S, T, C, Y, N or Q

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa optionally S, T, C, Y, N or Q

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa optionally S, T, C, Y, N or Q

<400>  4

Tyr Xaa Ala Tyr Pro Asp Xaa Val Pro Met Met Xaa 
1               5                   10          


<210>  5
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is optionally A, G, V, L, nL, I, M, F, W or P

<400>  5

Tyr Ser Xaa Tyr Pro Asp Ser Val Pro Met Met Ser 
1               5                   10          


<210>  6
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is optionally P, G, A, V, L, nL, I, M, F or W

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is optionally P, G, A, V, L, nL, I, M, F or W

<400>  6

Tyr Ser Ala Tyr Xaa Asp Ser Val Xaa Met Met Ser 
1               5                   10          


<210>  7
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is optionally D or E

<400>  7

Tyr Ser Ala Tyr Pro Xaa Ser Val Pro Met Met Ser 
1               5                   10          


<210>  8
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is optionally V, G, A, L, nL, I, M, F, W or P

<400>  8

Tyr Ser Ala Tyr Pro Asp Ser Xaa Pro Met Met Ser 
1               5                   10          


<210>  9
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (10)..(11)
<223>  Xaa is optionally M, G, A, V, L, nL, I, F, W or P

<400>  9

Tyr Ser Ala Tyr Pro Asp Ser Val Pro Xaa Xaa Ser 
1               5                   10          


